RecruitingNot ApplicableNCT06488248

Endoscopic Third Ventriculostomy vs. Ventriculoperitoneal Shunt in Idiopathic Normal Pressure Hydrocephalus (ENDOVEST)

Endoscopic Third Ventriculostomy Compared to Ventriculoperitoneal Shunt as Treatment for Idiopathic Normal Pressure Hydrocephalus (ENDOVEST): A Randomized Trial


Sponsor

University Hospital, Basel, Switzerland

Enrollment

150 participants

Start Date

Jan 17, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The aim of this single-center, two-arm, open-labeled, randomized controlled clinical study is to compare two surgical interventions, endoscopic third ventriculostomy and ventriculoperitoneal shunt, in treating idiopathic normal pressure hydrocephalus in terms of clinical improvement.


Eligibility

Min Age: 40 Years

Inclusion Criteria8

  • >40 years of age
  • Symptom duration ≥3 months, <24 months
  • No antecedent head trauma, ICH, meningitis, or other cause of secondary hydrocephalus
  • MUST show gait/balance disturbance, PLUS cognition impairment AND/OR urinary dysfunction.
  • Ventricular enlargement (Evans Index > 0.3) not attributable to cerebral atrophy or congenital enlargement
  • No macroscopic obstruction to cerebrospinal fluid (CSF) flow Spinal Tap-Test
  • Opening pressure (on lateral decubitus): <24cmH2O
  • Clinical improvement in at least one of the main symptoms after 40-50ml withdrawal of CSF

Exclusion Criteria7

  • ≤40 years of age
  • No informed consent
  • Other neurologic, psychiatric or general medical condition which is sufficient to explain the presenting symptoms.
  • Previous cranial neurosurgical interventions
  • Other associated dementia syndromes
  • Incapacity to walk
  • Pregnancy and breastfeeding women

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREEndoscopic third ventriculostomy (ETV)

The procedure is performed using an endoscope (LOTTA® system, Karl Storz Endoscopes, Germany; Minop®, BBraun, Tuttlingen, Germany or equivalent). The intervention is carried out under general anesthesia, with the procedure typically lasting around 60 minutes.

PROCEDUREVentriculoperitoneal shunt (VPS)

The procedure entails the insertion of a catheter into both the ventricular system and the peritoneal cavity, connected to a programmable valve that regulates cerebrospinal fluid flow. The choice of programmable valve (Codman Hakim or Codman Certas Programmable Valves, Integra, Plainsboro, USA; Strata valve, Medtronic, Minneapolis, USA; Sophysa, Orsay, France; Miethke proGAV, Aesculap, Tuttlingen, Germany) is at the surgeon's discretion. The preoperative valve setting is preset to a pressure level between 85 - 135 mmH2O. The VPS procedure is conducted under general anesthesia and typically lasts approximately 90-120 minutes.


Locations(1)

Department of Neurosurgery, University Hospital of Basel

Basel, Switzerland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06488248


Related Trials